248249-56-1 Usage
Uses
Used in Pharmaceutical Industry:
(2-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-methanol is used as a pharmaceutical compound for its potential anti-inflammatory properties, offering a therapeutic option for treating inflammation-related conditions.
Used in Antimicrobial Applications:
In the field of antimicrobial research, (2-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-methanol is utilized as an antimicrobial agent, potentially effective against various types of bacteria and other microorganisms, contributing to the development of new antibiotics.
Used in Anticancer Research:
(2-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-methanol is employed as an anticancer agent in oncology research, exploring its potential to inhibit the growth and proliferation of cancer cells, and possibly offering new avenues for cancer treatment.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, (2-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-methanol is used as a subject of study for its potential therapeutic effects, with the aim of understanding its mechanisms of action and optimizing its properties for various medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 248249-56-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,8,2,4 and 9 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 248249-56:
(8*2)+(7*4)+(6*8)+(5*2)+(4*4)+(3*9)+(2*5)+(1*6)=161
161 % 10 = 1
So 248249-56-1 is a valid CAS Registry Number.
248249-56-1Relevant articles and documents
Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
-
, (2008/06/13)
The present invention relates to a pharmaceutical composition for the hepatoprotection and treatment of liver diseases comprising as an active ingredient a dihydroxyphenyl derivative represented by the following formula (1), pharmaceutically acceptable acid addition salt or stereochemical isomer thereof together with a pharmaceutically acceptable inert carrier: 1in which in which A, B, D and E are defined as described in the specification.